Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy.

821Background: The CORRECT study showed significant overall survival (OS) improvement in the regorafenib (REG), compared with the placebo group in metastatic colorectal cancer (mCRC) which progress...